Treatment With Autologous Skeletal Myoblasts

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00975234
Recruitment Status : Terminated (Lack of recruitment)
First Posted : September 11, 2009
Last Update Posted : June 8, 2012
Fina Biotech
Information provided by (Responsible Party):
Clinica Universidad de Navarra, Universidad de Navarra

Brief Summary:
The purpose of this study is to determine the benefit of autologous skeletal myoblast injection in patients with old myocardial infarction and ventricular dysfunction versus conventional revascularisation therapy.

Condition or disease Intervention/treatment Phase
Old Myocardial Infarction Procedure: Intra-lesion injection of autologous skeletal myoblasts Procedure: Revascularisation Phase 2

Detailed Description:
Ischaemic heart disease is one of the main causes of mortality and morbidity. In particular, myocardial infarction (MI) is of special significance, as the heart muscle cannot regenerate so a region's necrosis leads to the formation of a fibrous scar. Depending on the area affected by the scar, infarction can lead to a progressive and irreversible decline in cardiac function, giving way to heart failure (HF) syndrome. The molecular basis of congestive heart failure is the absence of cardiac stem cells capable of regenerating cardiac muscle. In the skeletal muscle, there are cells located beneath the basal membrane with are capable of regenerating muscle fibres; they are known as myoblasts. There are several studies with autologous myoblasts, either by direct administration during surgery or percutaneously, which could distinguish between the effect of revascularisation surgery and that of the myoblast injection. The objective of this study is compare improvement in global and regional cardiac function in patients with old MI obtained by aortocoronary bypass surgery with intracardiac administration of autologous skeletal myoblasts versus standard aortocoronary bypass surgery treatment.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase II, Randomised, Controlled Study of Treatment With Revascularisation Surgery With or Without Injection of Autologous Skeletal Myoblasts in Patients With Old Myocardial Infarction
Study Start Date : May 2009
Actual Primary Completion Date : January 2010
Actual Study Completion Date : January 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Arm Intervention/treatment
Experimental: Skeletal myoblasts
Patients who are receiving skeletal myoblasts
Procedure: Intra-lesion injection of autologous skeletal myoblasts
Intra-lesion injection

Procedure: Revascularisation
Revascularisation surgery

Placebo Comparator: Placebo
Revascularisation surgery
Procedure: Revascularisation
Revascularisation surgery

Primary Outcome Measures :
  1. The primary efficacy endpoints will be evaluate the ejection fraction and wall motion score index measured by M-mode and echocardiography 12 months after surgery. [ Time Frame: 12 months after surgery ]

Secondary Outcome Measures :
  1. Secondary efficacy endpoints are viability, perfusion and thickening and incidence of cardiac arrhythmias. [ Time Frame: 12 month after surgery ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   30 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with a diagnosis of coronary disease obtained by coronary angiography who require conventional aortocoronary bypass surgery.
  • History of myocardial infarction with evidence of regional akinesis (or dyskinesia) for more than 4 weeks and less than 10 years.
  • Ejection fraction from 25% to 45%.
  • Evidence of no regional viability by dobutamine echocardiography.
  • Aged from 30-80 years old.
  • Negative serology to HIV, HBV and HCV.
  • Patients without organ dysfunction.
  • Negative pregnancy test (women of childbearing age).
  • Informed consent granted.

Exclusion Criteria:

  • History of myocardial infarction in the 4 weeks prior to the inclusion in the study.
  • Prior history of tachycardia or ventricular fibrillation (except in patients with DAI device).
  • History of cancer (except basocellular carcinoma) or prior treatment with chemotherapy.
  • The patient should not suffer from any concomitant severe and/or uncontrolled medical condition.
  • Patients who, due to their geographical, psychiatric or social status, have difficulties in meeting the conditions established in the protocol.
  • Pregnant or beast feeding women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00975234

Hospital Clínico Universitario de Santiago
Santiago de Compostela, Galicia, Spain, 15706
Clínica Universitaria de Navarra
Pamplona, Navarra, Spain, 31008
Hospital Gregorio Marañón
Madrid, Spain, 28007
Hospital Clínico San Carlos
Madrid, Spain, 28040
Hospital Clínico Universitario de Salamanca
Salamanca, Spain, 37007
Hospital La Fe
Valencia, Spain, 46009
Sponsors and Collaborators
Clinica Universidad de Navarra, Universidad de Navarra
Fina Biotech
Study Director: Felipe Prósper, MD, PhD Clinica Universidad de Navarra

Responsible Party: Clinica Universidad de Navarra, Universidad de Navarra Identifier: NCT00975234     History of Changes
Other Study ID Numbers: Mio/Reg/Quirur/Aleatorizado
First Posted: September 11, 2009    Key Record Dates
Last Update Posted: June 8, 2012
Last Verified: June 2012

Keywords provided by Clinica Universidad de Navarra, Universidad de Navarra:
Intra-lesion injection of autologous myoblasts

Additional relevant MeSH terms:
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases